FDA Performance Tracker
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Keeping Track: J&J Esketamine, Sanofi Caplacizumab Lead Off September Submissions; US FDA Says No To Nucala
Keeping Track: AstraZeneca Wins Approval For Lumoxiti, AbbVie Expands Label For Venclexta With MRD Data, and FDA Delays Acorda's Inbrijia NDA
New molecular entities and therapeutic biologics cleared by the US FDA's Center for Drug Evaluation and Research. Our FDA Performance Tracker chart is updated regularly with new approvals.
Biologics cleared by the Center for Biologics Evaluation and Research, including vaccines, cellular products, antitoxins and immunoglobulins. Updated regularly with new approvals.
Biosimilar applications using the 351(k) pathway under review at US FDA. Updated upon new submissions.
Drug review recommendations from FDA advisory panels, including regulatory actions. Updated weekly.
Details of action letters issued by US FDA, regularly updated with new announcements.
Qualified Infectious Disease Product Designations granted by FDA. Updated upon new designations.
Estimated FDA review deadlines for pending applications. Updated weekly.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.